Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 56Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 29Neoplasm Metastasis 23Glioblastoma 23Colonic Neoplasms 23Rectal Neoplasms 19Ovarian Neoplasms 16Neoplasms 15Brain Neoplasms 12Lung Neoplasms 11Pancreatic Neoplasms 10Glioma 10Fallopian Tube Neoplasms 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Gliosarcoma 7Adenocarcinoma of Lung 7Kidney Neoplasms 6Liver Neoplasms 5Astrocytoma 5Sarcoma 4Recurrence 4Oligodendroglioma 4Melanoma 4Uterine Cervical Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

Everolimus 7lutetium Lu 177 dotatate 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1fosbretabulin 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1Serotonin 1Quality of Life 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroendocrine Tumors × Bevacizumab × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡